Doctor of Osteopathy Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Sarah Bonaffini

Ophthalmology Margate City, NJ Doctor of Osteopathy

NPI 1457892119 CMS profile 8789645

9701 Ventnor Ave Ste 201, Margate City, NJ 08402

Open in the dashboard

General payments

$17,905

122 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sarah Bonaffini of Margate City, NJ is reported in the CMS Open Payments database as having received $17,905 across 122 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,542 54
2024 General $2,045 34
2023 General $749 21
2022 General $175 3
2021 General $14 1
2020 General $380 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sarah Bonaffini
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Sarah Bonaffini were reported at $14,542. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Sarah Bonaffini Ophthalmology median Middle half National median
2019 $0 $258 $104–$655 $163
2020 $380 $126 $45–$321 $114
2021 $14 $205 $76–$534 $132
2022 $175 $266 $100–$678 $149
2023 $749 $308 $117–$745 $160
2024 $2,045 $340 $127–$846 $164
2025 $14,542 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Bausch & Lomb Americas Inc. $13,848 45 payments
  2. AbbVie, Inc. $1,280 6 payments
  3. Alcon Vision LLC $673 12 payments
  4. RxSight Inc $301 6 payments
  5. Regeneron Healthcare Solutions, Inc. $239 2 payments
  6. Tarsus Pharmaceuticals, Inc. $226 13 payments
  7. Allergan Inc. $205 6 payments
  8. Carl Zeiss Meditec, Inc. $185 2 payments
  9. Sun Pharmaceutical Industries Inc. $180 10 payments
  10. Horizon Therapeutics plc $174 2 payments
  11. Other $595 18 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Compensation for serving as faculty or as a speaker for a medical education program $11,938 8 payments
  2. Food and Beverage $4,069 96 payments
  3. Consulting Fee $1,150 1 payment
  4. Travel and Lodging $566 12 payments
  5. Education $183 5 payments
Products named General payments · program years 2020–2025
  1. MIEBO $13,353 31 payments
  2. XIIDRA $11,337 24 payments
  3. Clareon $494 7 payments
  4. RXSIGHT LIGHT DELIVERY DEVICE (LDD) $301 6 payments
  5. RXSIGHT CONTACT LENS $301 6 payments
  6. LIGHT ADJUSTABLE LENS (LAL) $301 6 payments
  7. RXSIGHT INJECTOR CARTRIDGE $301 6 payments
  8. RXSIGHT INJECTOR HANDPIECE $301 6 payments
  9. EYLEA HD $239 2 payments
  10. XDEMVY $226 13 payments
  11. Other $2,415 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

1,211

Median for Ophthalmology: 891

Drug cost

$126,807

Median for Ophthalmology: $68,233

Branded share of claims

42.5%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 35 $34,869
Xiidra Lifitegrast Brand 14 $25,733
Cyclosporine Generic 30 $18,416
Miebo Perfluorohexyloctane/Pf Brand 19 $14,161
Cequa Cyclosporine Brand 17 $13,579
Prednisolone Acetate Generic 154 $4,663
Brimonidine Tartrate Generic 90 $3,840
Erythromycin Erythromycin Base Brand 181 $2,112
Latanoprost Generic 207 $2,036
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 106 $1,867

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$154,723

Of which drugs: $790

Medicare patients

824

Average age 74

Services billed

1,725

525 women, 299 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 33%
Ischemic heart disease 29%
Chronic kidney disease 21%
COPD 18%
Depression 17%
Osteoporosis 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $133
$133 — —
EYLEA HD
  • Regeneron Healthcare Solutions, Inc. $121
$121 — —
LUMIGAN
  • AbbVie, Inc. $70
$70 — —
XIIDRA
  • Bausch & Lomb Americas Inc. $50
$50 14 —
Cequa
  • Sun Pharmaceutical Industries Inc. $49
$49 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

122 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record